ATAI Investor Day Presentation Deck

Exploratory endpoint analysis shows clinically meaningful learning effects - ISLT (PK study - young caucasians) (Cohen's d effect size) 1.40 1.20 1.00 0.80 0.60 0.40 0.20 0.00 -0.20 -0.40 -0.60 -0.80 RL - 007 40 mg low dose enhanced learning with single & 7 day TID dosing (Phase 1 exploratory endpoints - 6 patients/dose) Single dose 7 day TID dosing atai LIFE SCIENCES 0.53 PBO-single 1.22 40-single I I I -0.57 150-single -0.29 450-single (Cohen's d effect size) 1.50 1.00 0.50 0.00 -0.50 -1.00 -1.50 -0.03 PBO-7d TID 0.97 140-7d TID -0.83 150-7d TID Cohen's d = 0.2 considered a 'small' effect size, 0.5 a 'medium' effect size & 0.8 a 'large' effect size -0.99 450-7d TID | 30

View entire presentation